Premium
Rifampicin‐induced lupus erythematosus
Author(s) -
Patel G. K.,
Anstey A. V.
Publication year - 2001
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1046/j.1365-2230.2001.00809.x
Subject(s) - rifampicin , medicine , clarithromycin , ciprofloxacin , drug , lupus erythematosus , dermatology , pharmacology , immunology , antibiotics , pathology , tuberculosis , microbiology and biotechnology , biology , antibody , helicobacter pylori
Rifampicin has been prescribed throughout the world for over 20 years, yet only four cases of rifampicin‐induced lupus erythematosus (LE) have been reported. Rifampicin‐induced LE is associated with combination therapy with clarithromycin or ciprofloxacin. These drugs are all metabolized through the cytochrome P450 liver enzyme system and combined usage may lead to higher rifampicin blood levels. Drug‐induced LE differs from systemic LE; cutaneous manifestations, although uncommon, are an important clue to the diagnosis. We report a case of rifampicin‐induced LE presenting with florid cutaneous features.